Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02136940 · ClinicalTrials.gov registry record · Phase 2
Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
A Phase 2 study, sponsored by Amakem.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
NCT02136940 is a Phase 2 study that has completed, run by Amakem. The registered enrollment target is 103 participants.
The verdict
NCT02136940, a Phase 2 study, has completed, sponsored by Amakem.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
Study Summary
The objective of this parallel group study is to evaluate the safety, tolerability and efficacy of AMA0076 in reduction of intraocular pressure in subjects with primary open-angle glaucoma or ocular hypertension.
Interventions
- DRUG Placebo
- DRUG AMA0076
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2014-04 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02136940
The ClinicalTrials.gov registry entry for NCT02136940 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amakem, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02136940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02136940 about?
NCT02136940 is a clinical study titled "Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension". The objective of this parallel group study is to evaluate the safety, tolerability and efficacy of AMA0076 in reduction of intraocular pressure in subjects with primary open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT02136940?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2014-04. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02136940?
The interventions under investigation include: Placebo (DRUG), AMA0076 (DRUG).
Who is sponsoring clinical trial NCT02136940?
This trial is sponsored by Amakem, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.